Navigation Links
Denosumab delayed time to first skeletal-related side effect
Date:12/10/2010

SAN ANTONIO For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine and director of the Clinical Breast Cancer Program at the Arizona Cancer Center, University of Arizona, Tucson.

The Food and Drug Administration approved denosumab, sold by Amgen as XGEVA starting Nov. 18, 2010, for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Previous results from this Phase III trial indicated that denosumab was superior to zoledronic acid in delaying the time to first on-study, skeletal-related side effects, such as fracture, radiation to bone, surgery to bone or spinal cord compression in patients with breast cancer and bone metastases. These results detail an additional four months of blinded treatment.

Stopeck and colleagues randomized 2,046 patients with advanced breast cancer to receive either 120 mg of subcutaneous denosumab or 4 mg of intravenous zoledronic acid every four weeks. Both of these drugs inhibit osteoclasts, or the cells that break down bone, therefore, all patients took calcium and vitamin D daily.

Denosumab was better at delaying the time to first on-study, skeletal-related event by 18 percent and the time to first and subsequent event by 22 percent. The median time to first on-study, skeletal-related event was five months longer for the denosumab group compared to the zoledronic acid group.

Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2 percent for those taking denosumab and 97.4 percent for those taking zoledronic acid. Jaw osteonecrosis occurred in 2.5 percent of patients taking denosumab and 1.8 percent of those taking zoledronic acid.

Stopeck thinks these results will be practice changing. "We now have an alternative to zoledronic acid that is more convenient, less toxic and more effective for patients with bone metastases," she said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Pain Relief Often Delayed for Cancer Patients
2. Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds
3. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
4. New study confirms positive effects of delayed school start times
5. For HIV-positive patients, delayed treatment a costly decision
6. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
7. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
8. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
9. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
10. MSU launches first anti-counterfeiting research program
11. AMA Joins First Lady in Fight Against Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania addiction ... address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found at ... with its redesigned and retooled website. The treatment center has also revamped its ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, and ... 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive director ...
(Date:1/23/2017)... ... ... plastic balance boards have been around since at least the 1950s and are a great ... and only balance board to use a patent-pending design featuring high-pressure inflation technology and drop-stitch ... well as skill-level adjustable for all ages and abilities. The board can be rolled ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... North America for the scientific development, healthcare training and clinical application of medical ... its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , For the ...
(Date:1/23/2017)... ... 2017 , ... Moisture measurement is a necessary process step ... to success. Selecting an inappropriate measurement method can cause costly errors, and poor ... equipment. Rare or expensive substances are wasted and production may even be stopped ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
(Date:1/23/2017)... , 23 janvier 2017  ResMed (NYSE : RMD), ... , Floride) ont annoncé aujourd,hui qu,ils se sont mis ... existants entre les parties. BMC et 3B seront autorisés ... de droits à ResMed, et ResMed effectuera le paiement ... pour clore le litige de Floride entre les deux ...
(Date:1/23/2017)... -- InDex Pharmaceuticals Holding AB (publ) today announced that ... the European Crohn,s and Colitis Organisation (ECCO). The ECCO congress is ... inflammatory bowel disease (IBD). The congress is held in ... ... having been selected to present data at the largest IBD congress ...
Breaking Medicine Technology: